The FDA has extended the review period for Baricitnib, a new once-a-day drug for rheumatoid arthritis.
The drug is designed by Eli Lilly and Incyte Corp. The extension will allow for further testing and drug application, and was awarded after the initial review period completed in January.
“At Lilly we are committed to improving the lives of people with life-long chronic diseases such as rheumatoid arthritis,” J. Anthony Ware, senior vice president of product development at Eli Lilly, said.
“We will continue to work closely with the FDA throughout the review process and we believe that baricitinib has the potential to be an effective treatment of choice, especially for those patients from whom current therapies are not adequately addressing their disease.”
Studies have shown that baricitinib reduces inflammation and helps keep autoimmune disorders
in check.
Eli Lilly granted extended review period for arthritis drug
Alerts Sign-up